research Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination
A woman developed alopecia after her second Pfizer vaccine but regrew her hair with treatment and had no issues after a booster shot.
Search
for
Sort by
Research
870-900 / 1000+ results research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
research Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
research Towards cell-based therapy of alopecia areata: Autologous human Vδ2+ Foxp3+ γδTreg cells restore hair-follicle immune privilege and promote hair regrowth in human alopecia areata models ex vivo and in vivo
Special cells can help regrow hair in alopecia areata.
research Combined C3b and Factor B Autoantibodies and MPGN Type II
The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
research 2‐deoxy D‐glucose treatment does not elicit a hair growth response in alopecia areata
2-deoxy D-glucose does not help with hair regrowth in alopecia areata.
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
research Baricitinib (Olumiant)
Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Integrated single-cell chromatin and transcriptomic analyses of peripheral immune cells in patients with alopecia areata
Early intervention with JAK inhibitors may prevent alopecia areata progression.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Identification of BST2 as a biomarker for alopecia areata in both mice and humans
BST2 is a key marker for hair loss disease alopecia areata.
research 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
research Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
research Alopecia areata mit gutem Ansprechen auf Tofacitinib
Tofacitinib helped regrow hair in a woman with alopecia areata.
research Novel investigational drugs for alopecia areata and future perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
research The investigation of selective sphingosine-1 phosphate receptor 1&4 modulator to treat alopecia areata mouse model 2881
The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
research Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases
Targeted cytokine treatments may help with alopecia areata, but more research is needed.
research JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
Baricitinib shows promise for treating alopecia areata with mild side effects.
research Ivarmacitinib stimulates hair regrowth in severe alopecia areata
Ivarmacitinib effectively regrows hair in severe alopecia areata.
research Aim to alleviate alopecia areata with newly available agents
New treatments like JAK inhibitors offer hope for better alopecia areata management.
research Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research 224 Humoral immune response to COVID-19 vaccination in psoriasis patients on biologic therapy is impaired compared to healthy controls
Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.